Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1621-1627

  Kato, Ken ^a   Chin, Keisho ^b   Yoshikawa, Takaki ^c   Yamaguchi, Kensei ^d   Tsuji, Yasushi ^e   Esaki, Taito ^f   Sakai, Kenji ^g   Kimura, Masami ^h   Hamaguchi, Tetsuya ^a   Shimada, Yasuhiro ^a   Matsumura, Yasuhiro ⁱ   Ikeda, Ryuji ^j  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e Tonan Hospital   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^h Health Insurance Hitoyoshi General Hospital   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^j NIPPON KAYAKU CO LTD   (Japan)

more..

Author keywords

Gastric cancer; Micellar nanoparticle; NK105; Phase II study; Second line

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; NANOPARTICLE; NK 105; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MICELLE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTE; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEMOGRAPHY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MICELLES; MIDDLE AGED; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866735036     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9709-2     Document Type: Article

References (30)

1. GLOBOCAN database http://www-dep.iarc.fr/globocan/globocan. html.
2. Vital Statistics Japan (Ministry of Health, Labour and Welfare)
3. Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-1069
4. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435-1442
5. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
6. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study group. J Clin Oncol 24:4991-4997
7. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
8. Hashimoto K, Takashima A, Nagashima K et al (2009) Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol 136:1059-1064
9. Thuss-Patience PC, Kretzschmar A, Deist T, et al (2009) Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol;27:15s, (suppl; abstr 4540).
10. Wilson D, Hiller L, Geh JI (2005) Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 17:81-90
11. Wesolowski R, Lee C, Kim R (2009) Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 10:903-912
12. Kodera Y, Ito S, Mochizuki Y et al (2007) Phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 27:2667-2671
13. Hironaka S, Zenda S, Boku N et al (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14-18
14. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259
15. Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 23:71-75
16. Crown J, O'Leary M (2000) The taxanes: an update. Lancet 355:1176-1178
17. Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263-1268
18. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004-1014
19. Kloover JS, den Bakker MA, Gelderblom H et al (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90: 304-305
20. Hamaguchi T, Matsumura Y, Suzuki M et al (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92:1240-1246
21. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392
22. Maeda H, Wu J, Sawa T et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271-284
23. Hamaguchi T, Kato K, Yasui H (2007) A Phase I and pharmacokinetic study of NK105, a paclitaxel -incorporating micellar nanoparticle formulation. Br J Cancer 97:170-176
24. Therasse P, Arbuck S, Eisenhauer E et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
25. Common Terminology Criteria for Adverse Event (CTC-AE Version 3.0, March 31, 2003).
26. Green S, Dahlberg S (1992) Planned versus attained design in Phase II clinical trials. Stat Med 11:853-862
27. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86:1203-1209
28. Boddy AV, Plummer ER, Todd R et al (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 11:7834-7840
29. Ibrahim NK, Desai N, Legha S et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044
30. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803